ClinicalTrials.gg
RecruitingNCT07101770Updated Dec 1, 2025

A Prediction Model in Pregnant Women With Aplastic Anemia

An observational study in Aplastic Anemia, Pregnancy and Prediction Model, sponsored by Peking University People's Hospital. Recruiting at 1 site in China. Open to female participants aged 20 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-12-01.

Sponsored by Peking University People's Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
300
Ages
20 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies in Anemia, Aplastic by Peking University People's Hospital — 9 open to participants now, 9 under way, 1 of them phase 3. Anemia, Aplastic · Peking University People's Hospital.

Started
2025
the only one that year
Observational
3 of 10
3 open now
Registered
5th of 10
by date

Among the 10 studies in Anemia, Aplastic by Peking University People's Hospital, this one is the only one that started in 2025, is one of 3 observational ones, and was the 5th registered.

Anemia, Aplastic

373 studies on the registry are indexed under Anemia, Aplastic; 98 are open to participants now.

Browse Anemia, Aplastic studies →

Open to participants now

9 of the 10 studies in Anemia, Aplastic by Peking University People's Hospital are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 57 Anemia, Aplastic studies recruiting now, 20 (35%) set no upper age limit and 29 (51%) stop at 75 or younger; 37 take children under 18; 5 take healthy volunteers.

This study: 20 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Anemia, Aplastic by Peking University People's Hospital, or all of them as a file.
02

Study summary

Aplastic anemia (AA) is a rare haematologic disorder characterized by bone marrow failure and pancytopenia. Its occurrence during pregnancy is exceedingly rare but poses significant risks, including maternal hemorrhage, infections, and perinatal complications such as preterm birth and fetal growth restriction. Consequently, pregnancy with AA is highly perilous for both mothers and infants. Early management is critical to ensure the health of both the mother and the baby. However, there are currently no predictive tools available to assess adverse outcomes in pregnant women with AA. Our center plans to conduct a multicenter, combined retrospective and prospective cohort study.

Read the detailed description

The gestational period, a physiological condition linked to elevated physiological stress, induces significant cardiac remodeling and systemic hemodynamic adaptations in maternal organisms. AA, a rare but life-threatening hematologic disorder characterized by pancytopenia and bone marrow hypoplasia, poses profound challenges during pregnancy, with significant risks of maternal and perinatal morbidity and mortality. Physiological adaptations in pregnancy, including hemodilution and increased metabolic demands, exacerbate AA-related hematologic deficits, elevating risks of severe anemia, thrombocytopenia-related hemorrhage, and immunosuppression-associated infections. These outcomes underscore the critical need for dynamic risk stratification and tailored interventions.

Currently, most cohort studies on pregnant women with AA in China are retrospective, single-center studies with small sample sizes, resulting in insufficient data and a lack of multicenter, prospective cohort studies.

This study is a multicenter, retrospective and prospective observational study that will enroll pregnant women with aplastic anemia. It will collect baseline patient information and diagnostic data, conduct regular prospective follow-ups via questionnaires, telephone interviews, video consultations, online platforms, and in-person visits, and record treatment regimens, comorbidities, and prognostic outcomes. The study aims to provide comprehensive data on the epidemiology and clinical outcomes of pregnant women with aplastic anemia in China, and aimed to develop and validate a predictive model for adverse pregnancy outcomes in pregnant women with AA, with the goal of guiding early clinical decision-making and improving their overall health outcomes.

03

Conditions studied

  • Aplastic Anemia
  • Pregnancy
  • Prediction Model

Browse trials for

Keywords

  • aplastic anemia
  • pregnancy
  • prediction model
04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population included pregnant women with aplastic anemia 20 years of age or older. This study was conducted in strict accordance with the Declaration of Helsinki and was approved by ethics committees or central institutional review boards of the Peking University People's Hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. pregnant women who had aplastic anemia before pregnancy
  2. pregnant women with newly diagnosed aplastic anemia during pregnancy

Exclusion criteria

Exclusion Criteria:

  1. age less than 20 years
  2. without coagulation series results
  3. termination of pregnancy before 20 weeks of gestation
  4. multiple pregnancy
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • with adverse pregnancy outcomes

    Other: A combined retrospective and prospective observational follow-up

  • without adverse pregnancy outcomes

    Other: A combined retrospective and prospective observational follow-up

Interventions

  • OtherA combined retrospective and prospective observational follow-up

    A combined retrospective and prospective observational follow-up

06

What researchers measure

Primary outcomes

  1. Number of participants with Adverse pregnancy outcomes

    Incident of adverse pregnany outcomes include at least one of the conditions as follows: placental abruption (ultrasound to detect a retroplacental hematoma), amniotic fluid embolism (elevated fetal squamous cells, vernix, or meconium in maternal blood; prolonged PT, APTT, low fibrinogen, and elevated D-dimers), postpartum hemorrhage (≥500 mL blood loss within 24 hours of vaginal delivery or ≥1000 mL after cesarean delivery), postpartum infection (fever, leukocytosis, etc), maternal mortality, stillbirths (fetal death occurring at ≥20 weeks of gestation), preterm birth (delivery at \<37 weeks of gestation), low birthweight ( a newborn with birth weight \<2500 g), fetal growth restriction (a fetus with estimated fetal weight or abdominal circumference \<10th percentile for gestational age), neonatal intensive care unit admission, or neonatal mortality (death of a live-born infant within the first 28 days of life).

    Time frame: From the first visit to hospital during pregnancy to 42 days after delivery

Secondary outcomes

  1. Neonatal Apgar Score

    Apgar 1-minute, 5-minute, 10-minute scores

    Time frame: within 10 minutes after birth

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2025; primary completion for Jun 2030, 55 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2025
First posted
Aug 3, 2025
StartEst.
Nov 27, 2025
Primary completionEst.
Jun 30, 2030
CompletionEst.
Dec 31, 2030
Last update
Dec 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07101770
Collaborators
Tianjin Medical University General Hospital, Lanzhou University Second Hospital, The Affiliated Hospital of Inner Mongolia Medical University, General Hospital of Ningxia Medical University, Peking Union Medical College Hospital, Peking University Third Hospital, The First Affiliated Hospital of Anhui Medical University, Wuhan TongJi Hospital, Peking University First Hospital, Chinese PLA General Hospital, Second Xiangya Hospital of Central South University, The First Affiliated Hospital of Soochow University, Qilu Hospital of Shandong University, Shanxi Provincial People's Hospital, The First Affiliated Hospital of Zhengzhou University, Shandong Provincial Hospital, Shanxi Bethune Hospital, Yantai Yuhuangding Hospital, First Affiliated Hospital of Harbin Medical University, The Third Affiliated Hospital of Guangzhou Medical University, First Affiliated Hospital of Zhejiang University, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Responsible party
Xiao Hui Zhang (Principal Investigator, Peking University People's Hospital) — Principal investigator
First posted
Aug 3, 2025
Start date
Nov 27, 2025 (estimated)
Primary completion
Jun 30, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Dec 1, 2025

Study contacts

Xiaohui Zhang, MD
Contact
zhangxh@bjmu.edu.cn
+8613522338836
Qiuyu Guo, MD
Contact
qiuyu_guo@163.com
+8613661094882
Xiaohui Zhang, MD
principal investigator · Peking University People's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion